Within cNEUPRO, sAPPα and sAPPβ levels in CSF of MCI and AD patients with elevated total-tau and reduced Aβ1-42 CSF concentrations were compared to those from patients without a respective CSF biomarker profile. This evidence concerns the gene MAPT and Alzheimer disease.